In talking to virtual biotech experts, one learns quickly that almost everyone in this game takes slightly or drastically different approaches to building their companies. Some favor certain tech tools, while others innovate with their business models. Nimbus, for example, has a corporate structure that supports the formation of multiple LLCs to tackle specific targets and offers multiple exit opportunities to investors. AstraZeneca's ($AZN) iMed has taken some of the tech insights that went into Chorus and then added in some other components based on the needs of a neuroscience R&D venture.
Please feel free to chime in with any additional insights that could help biotech pros with their own virtual business ambitions.